- Prasfarma has announced a €32 million investment to expand its facilities in Manlleu, focusing on oncology drug production and sustainability.
- The expansion will include state-of-the-art technology, increased capacity for large-scale projects, and job creation in engineering, pharmacy, and chemistry.
Prasfarma has committed €32 million to expanding its facilities in Manlleu, reinforcing its focus on technological innovation and sustainability. The investment aims to enhance the production of oncology drugs while meeting the highest industry standards, including Annex I of Good Manufacturing Practices (GMP) for sterile products.
The upgraded facilities will incorporate cutting-edge technology to ensure quality and safety in drug manufacturing. Additionally, Prasfarma will use the expansion to support large-scale projects, fostering collaboration with strategic partners to drive innovation in the pharmaceutical sector.
Beyond corporate growth, the initiative will have a broader impact on the Manlleu community. The investment is expected to create new job opportunities for highly qualified professionals in engineering, pharmacy, and chemistry. Furthermore, Prasfarma has pledged to expand and donate green spaces around its facilities, contributing to the city’s environmental sustainability.
“This investment represents our commitment to technological advancement and responsible business practices,” the company stated. “By expanding our capabilities, we are not only strengthening Prasfarma and the STE Group but also creating value for the community and the industry as a whole.”
Stay ahead of trends and best practices
